HC Wainwright reaffirmed their buy rating on shares of Vir Biotechnology (NASDAQ:VIR - Free Report) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a $110.00 target price on the stock. HC Wainwright also issued estimates for Vir Biotechnology's FY2029 earnings at $2.25 EPS.
VIR has been the topic of several other reports. JPMorgan Chase & Co. lifted their target price on Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a report on Thursday, January 9th. Leerink Partners upped their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Needham & Company LLC reissued a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. Morgan Stanley upgraded shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $10.00 to $20.00 in a research report on Thursday, January 9th. Finally, Barclays dropped their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Vir Biotechnology has a consensus rating of "Moderate Buy" and an average target price of $34.83.
View Our Latest Research Report on VIR
Vir Biotechnology Trading Down 2.8 %
Shares of NASDAQ:VIR traded down $0.28 during midday trading on Friday, reaching $9.70. 939,852 shares of the company were exchanged, compared to its average volume of 3,508,119. The stock has a market cap of $1.34 billion, a PE ratio of -2.48 and a beta of 0.51. The business's fifty day moving average is $8.86 and its two-hundred day moving average is $8.50. Vir Biotechnology has a one year low of $6.56 and a one year high of $14.45.
Insider Buying and Selling at Vir Biotechnology
In other news, Director Vicki L. Sato sold 10,960 shares of the firm's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total transaction of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares of the company's stock, valued at approximately $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 15.60% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Blue Trust Inc. raised its stake in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock worth $30,000 after buying an additional 2,351 shares in the last quarter. nVerses Capital LLC purchased a new stake in shares of Vir Biotechnology during the 3rd quarter worth $56,000. KBC Group NV boosted its position in Vir Biotechnology by 136.5% during the fourth quarter. KBC Group NV now owns 8,970 shares of the company's stock valued at $66,000 after purchasing an additional 5,177 shares in the last quarter. CIBC Asset Management Inc purchased a new position in Vir Biotechnology in the fourth quarter valued at about $74,000. Finally, Captrust Financial Advisors bought a new position in Vir Biotechnology in the third quarter worth about $118,000. Institutional investors own 65.32% of the company's stock.
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Featured Articles
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
